Efficacy and Safety Study of Ticagrelor
Launched by GENERAL HOSPITAL OF CHINESE ARMED POLICE FORCES · Mar 14, 2013
Trial Information
Current as of June 21, 2025
Unknown status
Keywords
ClinConnect Summary
180 elective percutaneous coronary intervention patients with clopidogrel resistance were randomized to three groups, Group 1:received clopidogrel 75mg qd ;Group 2:received clopidogrel 150mg qd ; Group 3:received ticagrelor 90mg bid after PCI.Platelet funtion were tested by flowcytometric vasodilator-stimulated phosphoprotein(VASP) analysis before PCI,and 3days,7days and 1 month after PCI,respectively.The aim of our study is to compare the efficacy and safety of ticagrelor with clopidogrel
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1.Clinical diagnosis of ACS 2.undergoing PCI 3.with clopidogrel resistance
- Exclusion Criteria:
- • 1.any contraindication against the use of clopidogrel and ticagrel 2.Contradiction to aspirin and contrast medium 3.Life expectancy less than 1 year 4.Tumor or inflammatory diseases5. fibrinolytic therapy within 24 hours before randomization 6.a need for oral anticoagulation therapy 7. an increased risk of bradycardia 8.concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer 9.a history of asthma.
About General Hospital Of Chinese Armed Police Forces
The General Hospital of Chinese Armed Police Forces is a prestigious medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a leading sponsor of clinical studies, the hospital integrates military and civilian healthcare expertise to enhance medical practices and patient outcomes. Committed to upholding the highest ethical standards and regulatory compliance, the hospital fosters a collaborative environment that encourages scientific inquiry and the development of novel therapeutic interventions. Its multidisciplinary approach ensures comprehensive patient care while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
huiliang liu, doctor
Principal Investigator
Department of Cardiology of General Hospital of Chinese People's Armed Police Forces
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials